Puma Biotechnology Inc. (PBYI) announced Tuesday morning that the FDA has accepted its new drug application for PB272 for review. The drug is for the treatment of patients with early stage HER2-overexpressed/amplified breast cancer.
from RTT - Before the Bell http://ift.tt/2cZ506z
via IFTTT
No comments:
Post a Comment